A new orphan drug player - Amryt Pharma Plc- is coming to the London stock market heralding a promising pipeline and experienced leadership, arriving via a reverse takeover with Alternative Investment Market (AIM)-listed investment firm Fastnet Equity PLC.
The result will be a drug company with big plans and a product that is already on the market. That...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
